Klarris Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 55.58%
- Profit Growth 35.11%
- Ebitda 3.80%
- Net Worth 3.93%
- Total Assets 15.79%
About Klarris Pharmaceuticals
Klarris Pharmaceuticals Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 March 2020 (Four years and 11 months 3 days old ). Its registered office is in Satara, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Praveen Kumar and Bulbul Singh serve as directors at the Company.
Company Details
-
Location
Satara, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2020PTC338482
-
Company No.
338482
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Mar 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Klarris Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praveen Kumar
|
Director | 02-Mar-2020 | Current |
|
Bulbul Singh
|
Director | 02-Mar-2020 | Current |
Financial Performance of Klarris Pharmaceuticals.
Klarris Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 55.58% increase. The company also saw a substantial improvement in profitability, with a 35.11% increase in profit. The company's net worth moved up by a moderate rise of 3.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Klarris Pharmaceuticals?
In 2023, Klarris Pharmaceuticals had a public holding of 48.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sanvi Seeds & Bio Product Private LimitedPraveen Kumar and Bulbul Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Klarris Pharmaceuticals?
Klarris Pharmaceuticals has a workforce of 9 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Klarris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Klarris Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.